• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Five Year MS Data Might Change The Case For Investing In TG Therapeutics Stock (TGTX)

    Simply Wall St·10/17/2026 07:36:46
    语音播报
    • TG Therapeutics reported five year matching adjusted indirect comparison data indicating favorable relapse and disability progression outcomes for BRIUMVI versus ocrelizumab and ofatumumab in relapsing multiple sclerosis, based on reweighted ULTIMATE I/II trial patient data.
    • The MAIC suggests BRIUMVI may offer differentiated long term disability progression and relapse control within the anti CD20 class, which directly affects how payers, prescribers and patients might weigh it against entrenched competitors in routine treatment decisions.
    • We will examine how TG Therapeutics' investment narrative is influenced by BRIUMVI's five year MAIC data on disability progression.

    Scan how TG Therapeutics’ BRIUMVI story fits into the broader multiple sclerosis treatment race by lining it up against other late-stage biopharma plays on the 20 high quality undiscovered gems.

    TG Therapeutics Investment Narrative Recap

    TG Therapeutics asks you to believe BRIUMVI can support a durable neurology and autoimmune franchise while the company tightens its cost structure. The recent five year MAIC data strengthens the clinical story in relapsing multiple sclerosis but does not directly change the near term focus on subcutaneous development, label simplification and expanding prescriber adoption.

    The biggest short term swing factor is execution on subcutaneous BRIUMVI and dosing changes while keeping manufacturing and R&D spend from overwhelming earnings. Large outlays for new formulations and secondary sources, plus any fallout from governance investigations, remain the key operational risks that could weigh on margins and cash generation.

    The five year MAIC publication is the announcement that matters most here. It adds comparative context around relapse activity and disability progression for BRIUMVI versus ocrelizumab and ofatumumab using reweighted ULTIMATE I and II data, which feeds directly into how neurologists and payers may think about longer term treatment choices.

    For investors tracking catalysts, that kind of clinical durability signal intersects with the push into subcutaneous dosing and broader autoimmune indications because it supports the rationale to invest heavily in manufacturing and new studies. Positive analyst sentiment, such as recent target price moves, sits in the background but the real test is whether TG Therapeutics converts this evidence into stable market share and efficient spend.

    What The TG Therapeutics Consensus Is Building In

    TG Therapeutics' narrative projects US$1.8b revenue and US$619.2m earnings by 2029. Analysts are assuming 30.2% yearly revenue growth and an earnings increase of about US$177.7m from US$441.5m today.

    Uncover why TG Therapeutics' fair value indicates a 29% potential upside to its current price before that pricing gap closes.

    NasdaqCM:TGTX 1-Year Stock Price Chart
    NasdaqCM:TGTX 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate take on TG Therapeutics puts far more weight on the subcutaneous BRIUMVI program than on the new MAIC data. The most optimistic analysts were already penciling in about US$2.2b revenue and US$761.4m earnings by 2029. Those projections came before this five year comparison, so you may see opinions evolve and should compare several viewpoints yourself.

    Explore 4 other TG Therapeutics fair value estimates, including one that suggests as much as 228% upside from the current price!

    Reach Your Own Conclusion

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond TG Therapeutics?

    If the TG Therapeutics story has sharpened your thinking about risk, reward and clinical catalysts, it can help to compare it with other companies that fit different profiles. The Simply Wall St Screener lets you scan across markets quickly so you can line up TG Therapeutics against other opportunities that better match your own return and risk preferences.

    • If you want potential value combined with quality fundamentals and cash flow support, take a look at our 33 high quality undervalued stocks and see which businesses might deserve a closer look next.
    • If capital preservation is front of mind and you prefer steadier balance sheets, check out a 32 resilient stocks with low risk scores that may better align with a more defensively tilted approach.
    • If you are searching for companies with solid finances that still fly under the radar, scan through a 20 high quality undiscovered gems that could broaden your watchlist.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.